Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2023

12-09-2023 | Osteoporosis | Short Communication

The potential role of osteoporosis in unspecific [18F]PSMA-1007 bone uptake

Authors: Gaia Ninatti, Cristiano Pini, Fabrizia Gelardi, Samuele Ghezzo, Paola Mapelli, Maria Picchio, Lidija Antunovic, Alberto Briganti, Francesco Montorsi, Claudio Landoni, Martina Sollini, Arturo Chiti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2023

Login to get access

Abstract

Aim

Unspecific bone uptake is one of the main limitations of PET imaging with some PSMA-targeting radiopharmaceuticals, especially with [18F]PSMA-1007. We explored the potential association between osteoporosis and the occurrence of unspecific [18F]PSMA-1007 bone uptake investigating markers which might correlate with bone mineral density.

Materials and methods

We retrospectively analyzed treatment-naïve patients with a confirmed diagnosis of prostate adenocarcinoma who underwent staging [18F]PSMA-1007 positron emission tomography (PET). Qualitative image analysis was performed independently by three experienced nuclear medicine physicians. Patients were divided in two groups according to the presence/absence of unspecific bone uptake. Clinical information, blood count parameters (assessed within 3 months to the PET scan), body mass index (BMI), and bone density as estimated by computed tomography were collected. The Kruskal–Wallis and t-test were used to compare parameters.

Results

We analyzed 77 patients: 29 of them (38%) had unspecific bone uptake at [18F]PSMA-1007 PET, most commonly in the pelvic bones (69%) and ribs (62%). We did not find any significant difference in clinical parameters in the two groups. In patients with unspecific bone uptake, white blood cell, and neutrophil counts were significantly higher; in the same group, we observed lower values of BMI and bone density, although not statistically different.

Conclusions

We observed unspecific bone uptake on [18F]PSMA-1007 PET in more than 1/3 of patients. In this exploratory analysis, we found a significant correlation between blood count parameters and unspecific [18F]PSMA-1007 bone uptake. We may speculate that [18F]PSMA-1007 unspecific bone uptake could be associated with osteoporosis. This hypothesis needs to be further investigated in larger populations and exploring more specific markers of osteoporosis.
Literature
1.
Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD, et al. Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging; 2021;48:2978–89.
2.
Rauscher I, Krönke M, König M, Gafita A, Maurer T, Horn T, et al. Matched-pair comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61:51.
3.
Arnfield EG, Thomas PA, Roberts MJ, Pelecanos AM, Ramsay SC, Lin CY, et al. Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging. 2021;48:4495–507.
4.
Pattison DA, Debowski M, Gulhane B, Arnfield EG, Pelecanos AM, Garcia PL, et al. Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:763–776.
5.
Seifert R, Telli T, Opitz M, Barbato F, Berliner C, Nader M, et al. Unspecific PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scan and MRI triple validation in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2023;64(5):738–743.
6.
Hoberück S, Löck S, Borkowetz A, Sommer U, Winzer R, Zöphel K, et al. Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. 2021;11(1):109.
7.
Phelps TE, Harmon SA, Mena E, Lindenberg L, Shih JH, Citrin DE, et al. Predicting outcomes of indeterminate bone lesions on 18 F-DCFPyL PSMA PET/CT scans in the setting of high-risk primary or recurrent prostate cancer. J Nucl Med. 2023;64(3):395–401.
8.
Hammes J, Hohberg M, Täger P, Wild M, Zlatopolskiy B, Krapf P, et al. Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT. PLoS One. Public Library of Science; 2018;13:e0209613.
9.
Grünig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. Springer; 2021;48:4483.
10.
Ioppolo JA, Nezich RA, Richardson KL, Morandeau L, Leedman PJ, Price RI. Direct in vivo comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 and [18F]AlF-PSMA-11 in mice bearing PSMA-expressing xenografts. Appl Radiat Isot. Pergamon; 2020;161:109164.
11.
Piron S, Verhoeven J, Descamps B, Kersemans K, De Man K, Van Laeken N, et al. Intra-individual dynamic comparison of 18F-PSMA-11 and 68Ga-PSMA-11 in LNCaP xenograft bearing mice. Sci Rep. 2020;10(1):21068.
12.
Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):1–5.
13.
Maisto C, Aurilio M, Morisco A, De Marino R, Buonanno Recchimuzzo MJ, Carideo L, et al. Analysis of pros and cons in using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: production, costs, and PET/CT applications in patients with prostate cancer. Molecules. 2022;27(12):3862.CrossRefPubMedPubMedCentral
14.
Shigematsu Y, Hirai T, Kawanaka K, Shiraishi S, Yoshida M, Kitajima M, et al. Distinguishing Imaging features between spinal hyperplastic hematopoietic bone marrow and bone metastasis. Am J Neuroradiol. 2014;35:2013–20.
15.
16.
Appelman-Dijkstra NM, Papapoulos SE. Paget’s disease of bone. Best Pract Res Clin Endocrinol Metab. Baillière Tindall; 2018;32:657–68.
17.
Shellock FG, Morris E, Deutsch AL, Mink JH, Kerr R, Boden SD. Hematopoietic bone marrow hyperplasia: high prevalence on MR images of the knee in asymptomatic marathon runners. Am J Roentgenol. American Public Health Association; 1992;158:335–8.
18.
Salari N, Darvishi N, Bartina Y, Larti M, Kiaei A, Hemmati M, et al. Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. BioMed Central Ltd; 2021;16:1–13.
19.
Li Y, Hao W, Guan J, Li B, Meng L, Sun S, et al. Relationship between indices of circulating blood cells and bone homeostasis in osteoporosis. Front Endocrinol (Lausanne). Frontiers Media S.A.; 2022;13:2163.
20.
Dé Rique Turcotte Id A-F, O’connor S, Morin SN, Gibbs JC, Willie BM, Jean S, et al. Association between obesity and risk of fracture, bone mineral density and bone quality in adults: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252487.
21.
Vadera S, Osborne T, Shah V, Stephenson JA. Opportunistic screening for osteoporosis by abdominal CT in a British population. Insights into imaging 2023 141. SpringerOpen; 2023;14:1–8.
22.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. Springer Berlin Heidelberg; 2023;1466–86.
23.
Li H, Zhang X, Zhang Q, Zhang Q, Zhu X, Xie T, et al. The relationship between the monocyte-to-lymphocyte ratio and osteoporosis in postmenopausal females with T2DM: a retrospective study in Chinese population. Front Endocrinol (Lausanne). 2023;14:1–7.
24.
Gao K, Zhu W, Liu W, Ma D, Li H, Yu W, et al. The predictive role of monocyte-to-lymphocyte ratio in osteoporosis patient. Med (United States). Lippincott Williams and Wilkins; 2019;98.
25.
Lee JH, Kim JH, Hong AR, Kim SW, Shin CS. Optimal body mass index for minimizing the risk for osteoporosis and type 2 diabetes. Korean J Intern Med. 2020;35:1432–42.CrossRefPubMed
26.
Pickhardt PJ, Pooler BD, Lauder T, del Rio AM, Bruce RJ, Binkley N. Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications. Ann Intern Med. 2013;158:588–95.CrossRefPubMedPubMedCentral
27.
Jang S, Graffy PM, Ziemlewicz TJ, Lee SJ, Summers RM, Pickhardt PJ. Opportunistic osteoporosis screening at routine abdominal and thoracic CT: normative L1 trabecular attenuation values in more than 20 000 adults. Radiology. Radiological Society of North America Inc.; 2019;291:360–7.
28.
Palumbo C, Dalla Volta A, Zamboni S, Mazziotti G, Zamparini M, Triggiani L, et al. Effect of Degarelix administration on bone health in prostate cancer patients without bone metastases. The Blade study. J Clin Endocrinol Metab. 2022;107(12):3398–3407.
29.
Dalla Volta A, Palumbo C, Zamboni S, Mazziotti G, Triggiani L, Zamparini M, et al. Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study. J Clin Endocrinol Invest. 2023. https://​doi.​org/​10.​1007/​s40618-023-02150-z.CrossRef
30.
31.
Tuckermann J, Adams RH. Crosstalk between endothelial cells and bone in development, homeostasis and inflammatory disease. Nat Rev Rheumatol. Europe PMC Funders; 2021;17:608.
32.
Ganguly P, El-Jawhari JJ, Giannoudis PV, Burska AN, Ponchel F, Jones EA. Age-related changes in bone marrow mesenchymal stromal cells: a potential impact on osteoporosis and osteoarthritis development. Cell Transplant. 2017;26:1520–9.CrossRefPubMedPubMedCentral
33.
Morimoto R, Uehara S, Yatsushiro S, Juge N, Hua Z, Senoh S, et al. Secretion of L-glutamate from osteoclasts through transcytosis. EMBO J. 2006;25:4175–86.CrossRefPubMedPubMedCentral
34.
Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279–302.CrossRefPubMed
35.
Barrett-Connor E, Nielson CM, Orwoll E, Bauer DC, Cauley JA. Epidemiology of rib fractures in older men: Osteoporotic Fractures in Men (MrOS) prospective cohort study. BMJ. BMJ Publishing Group; 2010;340:798.
36.
Prins JTH, Van Lieshout EMM, Reijnders MRL, Verhofstad MHJ, Wijffels MME. Rib fractures after blunt thoracic trauma in patients with normal versus diminished bone mineral density: a retrospective cohort study. Osteoporos Int. 2020;31(2):225–231.
37.
Krappinger D, Kammerlander C, Hak DJ, Blauth M. Low-energy osteoporotic pelvic fractures. Arch Orthop Trauma Surg. 2010;130(9):1167–75.
38.
Kannus P, Palvanen M, Niemi S, Parkkari J, Järvinen M. Epidemiology of osteoporotic pelvic fractures in elderly people in Finland: sharp increase in 1970–1997 and alarming projections for the new millennium. Osteo Int. 2000;11(5):443.8.
39.
Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18.
40.
Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an endocrine society clinical practice guideline. J Clin Endocrinol Metab Oxford Academic. 2012;97:1802–22.CrossRef
41.
Vollnberg B, Alberts I, Genitsch V, Rominger A, Afshar-Oromieh A. Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging. 2022;49:3910–6.
42.
Chen MY, Franklin A, Yaxley J, Gianduzzo T, McBean R, Wong D, et al. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68 Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant? BJU Int. 2020;126:396–401.CrossRefPubMed
Metadata
Title
The potential role of osteoporosis in unspecific [18F]PSMA-1007 bone uptake
Authors
Gaia Ninatti
Cristiano Pini
Fabrizia Gelardi
Samuele Ghezzo
Paola Mapelli
Maria Picchio
Lidija Antunovic
Alberto Briganti
Francesco Montorsi
Claudio Landoni
Martina Sollini
Arturo Chiti
Publication date
12-09-2023
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-023-06424-9

Other articles of this Issue 1/2023

European Journal of Nuclear Medicine and Molecular Imaging 1/2023 Go to the issue

Review Article

[18F]-FDG PET in anal canal cancer: a systematic review and meta-analysis

Editorial

A look into the future: the role of PSMA beyond prostate cancer

Original Article

Integrated myocardial flow reserve (iMFR) assessment: optimized PET blood flow quantification for diagnosis of coronary artery disease

Image of the Month

Demonstration of therapy response to radioembolization with 90Y resin microspheres on 68Ga-PSMA PET/MRI in a patient with hepatocellular carcinoma

Original Article

Preclinical evaluation of a dual-receptor targeted tracer [68Ga]Ga-HX01 in 10 different subcutaneous and orthotopic tumor models

Original Article

Short-axis PET image quality improvement based on a uEXPLORER total-body PET system through deep learning